Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Authors
Hanna, C. R.O'Cathail, S. M.
Graham, J. S.
Saunders, Mark P
Samuel, L.
Harrison, M.
Devlin, L.
Edwards, J.
Gaya, D. R.
Kelly, C. A.
Lewsley, L. A.
Maka, N.
Morrison, P.
Dinnett, L.
Dillon, S.
Gourlay, J.
Platt, J. J.
Thomson, F.
Adams, R. A.
Roxburgh, C. S. D.
Affiliation
Cancer Research UK Glasgow Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Level 0, 1053 Great Western Road, Glasgow, G12 0YN, UK.Issue Date
2021
Metadata
Show full item recordCitation
Hanna CR, O’Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, et al. Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) Vol. 16, Radiation Oncology. Springer Science and Business Media LLC; 2021.Journal
Radiotherapy and OncologyDOI
10.1186/s13014-021-01941-zPubMed ID
34857017Type
Otherae974a485f413a2113503eed53cd6c53
10.1186/s13014-021-01941-z
Scopus Count
Collections
Related articles
- Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial.
- Authors: Grassi E, Zingaretti C, Petracci E, Corbelli J, Papiani G, Banchelli I, Valli I, Frassineti GL, Passardi A, Di Bartolomeo M, Pietrantonio F, Gelsomino F, Carandina I, Banzi M, Martella L, Bonetti AV, Boccaccino A, Molinari C, Marisi G, Ugolini G, Nanni O, Tamberi S
- Issue date: 2023 Oct
- Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
- Authors: Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB, Gruden JF, Christos PJ, Spinelli C, Gakuria J, Uppal M, Binder B, Elemento O, Ballman KV, Formenti SC
- Issue date: 2021 Jun
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
- Authors: Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A
- Issue date: 2019 Aug 1
- Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
- Authors: Kok PS, Forde PM, Hughes B, Sun Z, Brown C, Ramalingam S, Cook A, Lesterhuis WJ, Yip S, O'Byrne K, Pavlakis N, Brahmer J, Anagnostou V, Ford K, Fitzpatrick K, Bricker A, Cummins MM, Stockler M, Nowak AK, Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA
- Issue date: 2022 Jan 25
- The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision.
- Authors: Roselló S, Papaccio F, Roda D, Tarazona N, Cervantes A
- Issue date: 2018 Feb